An IPR warning shot for pharma that could resonate far and wide 09 Jan 15
Earlier this week US hedge fund investor Kyle Bass got the wires buzzing when he reportedly outlined his plans to wage an inter partes review (IPR) war on big pharma at the USPTO’s Patent Trial and Appeal Board (PTAB). According to Bass, pharmaceutical companies are ripe for attack because of their predilection for regurgitating what he claims are essentially the same products under slightly tweaked patents to extend their IP protection.
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
IAM explores how businesses can leverage IP rights as real assets beyond their traditional use. As the magazine addresses IP management issues without overly dwelling on legal matters, I consider it an eminently useful reference for innovative business executives.
Dr Frank Cuypers
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email